Transforming Trials 2030 with Sally Okun
The last two years have been driving many discussions of the need for change in the pharmaceutical industry, particularly in the clinical trial arena. Discussions have not always led to actions, however. Hi, I'm Tom Rhoads, CEO of Spencer Health Solutions. As we look towards 2022, I believe we will…
Ep. 102 - What FDA's Tyvyt Precedent Means for China; plus Translational Trendspotting
FDA and its advisory panel of oncology experts have repudiated the use of China-only data for regulatory submissions in the U.S. How will China's cancer companies adjust to this new regulatory environment? Plus, BioCentury's editors discuss the upcoming vote on Rob Califf, President Biden's nominee…
Ep. 103 - Califf’s Priorities for Second Stint as FDA Commissioner
Newly confirmed FDA commissioner Rob Califf will be prioritizing a proactive communications strategy, including combating misinformation about science, whilst guiding FDA through the pandemic and trying to keep the agency above Washington’s political fray. Plus, BioCentury’s editors discuss how lat…
Circulation October 11, 2016 Issue
Carolyn: Welcome to Circulation on the Run, your weekly podcast summary and backstage pass to the journal and its editors. I'm Dr. Carolyn Nam, Associate Editor from the National Heart Center and Duke-National University of Singapore. Today's featured discussion deals with the perspective piece …
MM+M Podcast 11.2.22: Industry’s drug-price fixes, payers’ birth-control restrictions, and Rob Califf’s thoughts on Alzheimer's coverage
Marc has a story from last week's Galien Forum, which touched on DTC in a price-sensitive era, recent drug-pricing legislation, and a fireside chat with FDA commissioner Rob Califf. Lecia discussed a new report that dug into how several large health insurers and pharmacy benefit managers are restri…
Ep. 182 - Merck’s IRA suit, Leqembi and MCEDs at ASCO
A lawsuit over the Inflation Reduction Act by Merck & Co. suit signals to Republicans that the pharma has no compunctions about attacking Democrats, the Biden administration and the president himself, said BioCentury Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Usdin an…
Ep. 184 - Califf's FDA reforms & Polaris' Schulman
FDA Commissioner Rob Califf’s biggest legacy could be his reform of FDA’s advisory committee process. But what is uncertain is whether his review can bring together enough consensus among agency leaders to drive a meaningful change, said Washington Editor Steve Usdin on the latest BioCentury This W…
Ep. 262 - EGFR Case Study, FDA & Politics
Twenty years of innovation in therapies targeting EGFR provides a case study in how generation of differentiated products against the target can drive market growth. On the latest BioCentury This Week podcast, BioCentury’s editors discuss EGFR as a prime example of the value in best-in-class develo…
Former FDA Commissioner on Fighting Medical Misinformation
Bob Harringson and former FDA commissioner Rob Califf discuss medical misinformation, its impact on public and individual health, and how to fight against it.
This podcast is intended for healthcare professionals only. To read a transcript or to comment, visit https://www.medscape.com/author/bob-h…
PODCAST-HAKUKONEET
Voit käyttää verkkosivustoamme etsiäksesi3,824,881-podcasteja ja195,784,805-jaksoja ihmisten, paikkojen tai aiheiden mukaan.
I have no special talent. I am only passionately curious, and
I listen to podcasts.
‐ Albert "Llamacorn" Einstein
MUOKKAA
Kiitos, kun autoit pitämään podcast-tietokantaa ajan tasalla.
